Inhibrx IPO év
Mi az Inhibrx IPO év?
A IPO év az Inhibrx, Inc. - 2020
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest
Mit csinál Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
ipo év -hoz hasonló cégek Inhibrx
- Acusensus Ltd nak IPO év 2019 van
- Grayscale Ethereum Trust (ETH) nak IPO év 2019 van
- Powerwrap Ltd nak IPO év 2019 van
- Powerwrap nak IPO év 2019 van
- National Rural Utilities Cooper nak IPO év 2019 van
- Listed Funds Trust nak IPO év 2019 van
- Inhibrx nak IPO év 2020 van
- Globally Local Technologies nak IPO év 2021 van
- uniQure N.V nak IPO év 2021 van
- Trustpilot plc nak IPO év 2021 van
- IQVIA nak IPO év 2021 van
- ACTIA S.A nak IPO év 2021 van
- Remark nak IPO év 2021 van